細胞融合技術を用いた遺伝子及び細胞治療剤、並びにその用途

Japanese Patent JP7300764

B2

The present invention relates to gene and cell therapy product using a cell fusion technology and use thereof, and more particularly, cells overexpressing hemagglutinin neuraminidase (HN) and fusion (F) proteins have effects of enhancing cell fusion with other cells by HN and F proteins, restoring damaged or dying cells or cells having gene abnormality to normal cells through the cell fusion. Therefore, a vector including genes encoding the HN and F proteins of the present invention or a cell transformed with the vector can be used as an active ingredient for prevention or treatment of neurodegenerative diseases or nerve diseases or degenerative muscular diseases or muscle diseases.

JP2014523871	Adjustment of pancreas beta cell growth
JP2017060472	RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-BINDING PROTEIN) β1(CTNNB1) GENE EXPRESSION USING SMALL INTERFERING NUCLEIC ACID (SINA)
JP2022529680	Gene therapy for fibroblast growth factor 23-related hypophosphatemic disease

Song, Jung Jun
Kim, Kiyun
John, Guesson

JP2021521927A

June 30, 2023

July 02, 2019

Click for automatic bibliography generation  

CURAMYS CO., LTD.

A61K48/00; A61K35/12; A61K35/15; A61K35/28; A61K35/30; A61K35/32; A61K35/34; A61K35/36; A61K35/50; A61K35/51; A61K35/545; A61K35/76; A61K35/761; A61K35/763; A61K38/16; A61K38/47; A61P9/00; A61P21/00

KR20170009464A

SK Patent Attorney Corporation
Akihiko Okuno
Hiroyuki Ito

Previous Patent: CAR expression vectors and CAR-expressing T cells

Next Patent: Model learning method and system for automatic judgment of degree of damage for each automobile part...